METHODS OF TREATMENT OF HEMATOLOGICAL MALIGNANT TUMORS AND THE USE OF BIOMARKERS AS AN INDICATOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATING THERAPY

摘要

In this application, in some embodiments, biomarkers are proposed for use in predicting the clinical sensitivity of hematological malignant tumors, such as non-Hodgkin's lymphoma, and the patient's response to treatment with an immunomodulatory agent, such as 3- (4-amino-1-oxo-1,3 -dihydroisoindol-2-yl) piperidine-2,6-dione, which is also known as lenalidomide or Revlimid®. Also in this application, in some embodiments, methods are proposed for treating or controlling non-Hodgkin's lymphomas, including, but not limited to, diffuse large B-cell lymphoma (DLBCL), using prognostic factors.